[ | E-mail ] Contact: ESMO Press Officemedia@esmo.orgEuropean Society for Medical Oncology@myesmo Vemurafenib + cobimetinib achieves significant progression-free survival and response rates in melanoma; Phase III trial data shows better outcomes with combination therapy than vemurafenib…
Source:New data on combination treatments for melanoma
Monday, September 29, 2014
New data on combination treatments for melanoma
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment